Proactive Investors - Run By Investors For Investors

Sareum Holdings jumps as it says new data on cancer drug to be released at top conference

The update is being presented in the form of two abstracts at the American Society of Clinical Oncology in Chicago
ovarian cancer graphic
Being trialled are two different approaches to treating ovarian cancer

Sareum Holdings PLC (LON:SAR) shares jumped on Tuesday as the firm said data from a potential cancer drug it developed will be showcased at the world’s leading oncology conference.

Updated results from a Phase I/IIa studies carried out on SRA737 by licensing partner Sierra Oncology will be delivered in the form of two abstracts at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1.

The Sareum-discovered drug candidate is what’s known as a checkpoint kinase 1 (CHK1) inhibitor.

CHK1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally by chemotherapy or radiotherapy.

The new treatment is being trialled in women with ovarian cancer, both as a single therapy and in harness with chemotherapy called gemcitabine.

The ASCO abstracts cover new data on the two approaches to treating the killer disease.

In afternoon trading, Sareum shares were 7.1% higher at 0.75p.

 -- Adds share price --

View full SAR profile View Profile

Sareum Holdings PLC Timeline

Big Picture
February 22 2019

Related Articles

Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
January 30 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use